These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 26755448)
41. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients. Comoli P; Cioni M; Tagliamacco A; Quartuccio G; Innocente A; Fontana I; Trivelli A; Magnasco A; Nocco A; Klersy C; Rubert L; Ramondetta M; Zecca M; Garibotto G; Ghiggeri GM; Cardillo M; Nocera A; Ginevri F Am J Transplant; 2016 Jul; 16(7):2106-16. PubMed ID: 26725780 [TBL] [Abstract][Full Text] [Related]
42. The quest to decipher HLA immunogenicity: Telling friend from foe. Tambur AR; McDowell H; Hod-Dvorai R; Abundis MAC; Pinelli DF Am J Transplant; 2019 Oct; 19(10):2910-2925. PubMed ID: 31165546 [TBL] [Abstract][Full Text] [Related]
43. Application of HLA molecular level mismatching in ethnically diverse kidney transplant recipients receiving a steroid-sparing immunosuppression protocol. Santos E; Spensley K; Gunby N; Worthington J; Roufosse C; Anand A; Willicombe M Am J Transplant; 2024 Jul; 24(7):1218-1232. PubMed ID: 38403189 [TBL] [Abstract][Full Text] [Related]
44. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. DeVos JM; Gaber AO; Knight RJ; Land GA; Suki WN; Gaber LW; Patel SJ Kidney Int; 2012 Sep; 82(5):598-604. PubMed ID: 22622504 [TBL] [Abstract][Full Text] [Related]
45. Comparison of human leukocyte antigen immunologic risk stratification methods in lung transplantation. Hiho SJ; Levvey BJ; Diviney MB; Snell GI; Sullivan LC; Westall GP Am J Transplant; 2024 May; 24(5):827-838. PubMed ID: 37981213 [TBL] [Abstract][Full Text] [Related]
46. Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor: Implications for clinical trials. Bentall A; Smith BH; Gonzales MM; Bonner K; Park WD; Cornell LD; Dean PG; Schinstock CA; Borrows R; Lefaucheur C; Loupy A; Stegall MD Am J Transplant; 2019 Aug; 19(8):2274-2283. PubMed ID: 30768833 [TBL] [Abstract][Full Text] [Related]
47. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss. Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905 [TBL] [Abstract][Full Text] [Related]
48. Impact of HLA mismatch at first kidney transplant on lifetime with graft function in young recipients. Foster BJ; Dahhou M; Zhang X; Platt RW; Smith JM; Hanley JA Am J Transplant; 2014 Apr; 14(4):876-85. PubMed ID: 24612783 [TBL] [Abstract][Full Text] [Related]
49. Donor-specific antibodies detected by single antigen beads alone can help risk stratify patients undergoing retransplantation across a repeat HLA mismatch. Lucisano G; Thiruvengadam S; Hassan S; Gueret-Wardle A; Brookes P; Santos-Nunez E; Willicombe M Am J Transplant; 2020 Feb; 20(2):441-450. PubMed ID: 31529621 [TBL] [Abstract][Full Text] [Related]
50. Immunologic outcome in elderly kidney transplant recipients: is it time for HLA-DR matching? Halleck F; Khadzhynov D; Liefeldt L; Schrezenmeier E; Lehner L; Duerr M; Schmidt D; Bamoulid J; Lachmann N; Waiser J; Budde K; Staeck O Nephrol Dial Transplant; 2016 Dec; 31(12):2143-2149. PubMed ID: 27369852 [TBL] [Abstract][Full Text] [Related]
51. Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss. Nocera A; Tagliamacco A; Cioni M; Innocente A; Fontana I; Barbano G; Carrea A; Ramondetta M; Sementa A; Basso S; Quartuccio G; Klersy C; Bertocchi M; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F Am J Transplant; 2017 Mar; 17(3):692-702. PubMed ID: 27501275 [TBL] [Abstract][Full Text] [Related]
52. Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients. Charnaya O; Jones J; Philogene MC; Chiang PY; Segev DL; Massie AB; Garonzik-Wang J Pediatr Nephrol; 2021 Dec; 36(12):3971-3979. PubMed ID: 34100108 [TBL] [Abstract][Full Text] [Related]
53. Human leukocyte antigen epitope mismatch loads and the development of de novo donor-specific antibodies in cardiothoracic organ transplantation. Bedford A; Jervis S; Worthington J; Lowe M; Poulton K Int J Immunogenet; 2022 Feb; 49(1):30-38. PubMed ID: 34904369 [TBL] [Abstract][Full Text] [Related]
54. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748 [TBL] [Abstract][Full Text] [Related]
55. Significant association between chronic antibody-mediated rejection and donor-specific antibodies against HLA-DRB rather than DQB in renal transplantation. Kobayashi T; Maruya E; Niwa M; Saji H; Kohara S; Katayama A; Takeda A; Watarai Y; Uchida K Hum Immunol; 2011 Jan; 72(1):11-7. PubMed ID: 20974206 [TBL] [Abstract][Full Text] [Related]
56. The impact of human leukocyte antigen mismatching on sensitization rates and subsequent retransplantation after first graft failure in pediatric renal transplant recipients. Gralla J; Tong S; Wiseman AC Transplantation; 2013 May; 95(10):1218-24. PubMed ID: 23478360 [TBL] [Abstract][Full Text] [Related]
57. Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation After Liver Transplantation. Kubal CA; Mangus R; Ekser B; Mihaylov P; Ceballos B; Higgins N; Chalasani N; Ghabril M; Nephew L; Lobashevsky A Liver Transpl; 2018 Aug; 24(8):1101-1108. PubMed ID: 30142248 [TBL] [Abstract][Full Text] [Related]
58. Sensitization trends after renal allograft failure: the role of DQ eplet mismatches in becoming highly sensitized. Singh P; Filippone EJ; Colombe BW; Shah AP; Zhan T; Harach M; Gorn C; Frank AM Clin Transplant; 2016 Jan; 30(1):71-80. PubMed ID: 26529289 [TBL] [Abstract][Full Text] [Related]
59. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. Gatault P; Kamar N; Büchler M; Colosio C; Bertrand D; Durrbach A; Albano L; Rivalan J; Le Meur Y; Essig M; Bouvier N; Legendre C; Moulin B; Heng AE; Weestel PF; Sayegh J; Charpentier B; Rostaing L; Thervet E; Lebranchu Y Am J Transplant; 2017 May; 17(5):1370-1379. PubMed ID: 27862923 [TBL] [Abstract][Full Text] [Related]
60. Utility of protocol kidney biopsies for de novo donor-specific antibodies. Parajuli S; Reville PK; Ellis TM; Djamali A; Mandelbrot DA Am J Transplant; 2017 Dec; 17(12):3210-3218. PubMed ID: 28805293 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]